# A Study for Participants With Metastatic Renal Cell Carcinoma

> **NCT00709995** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Enzastaurin
- **DRUG:** Sunitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00709995
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-30
- **Primary completion:** 2010-02-15
- **Final completion:** 2018-09-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709995, "A Study for Participants With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00709995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*